KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Enterprise Value (2016 - 2026)

Teva Pharmaceutical Industries (TEVA) has disclosed Enterprise Value for 18 consecutive years, with -$3.7 billion as the latest value for Q1 2026.

  • Quarterly Enterprise Value fell 121.12% to -$3.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$3.7 billion through Mar 2026, down 121.12% year-over-year, with the annual reading at -$3.6 billion for FY2025, 20.0% down from the prior year.
  • Enterprise Value for Q1 2026 was -$3.7 billion at Teva Pharmaceutical Industries, down from -$3.6 billion in the prior quarter.
  • The five-year high for Enterprise Value was -$1.3 billion in Q1 2022, with the low at -$3.7 billion in Q1 2026.
  • Average Enterprise Value over 5 years is -$2.3 billion, with a median of -$2.1 billion recorded in 2024.
  • The sharpest move saw Enterprise Value skyrocketed 38.0% in 2025, then plummeted 121.12% in 2026.
  • Teva Pharmaceutical Industries' Enterprise Value stood at -$2.0 billion in 2022, then plummeted by 60.74% to -$3.2 billion in 2023, then increased by 8.25% to -$3.0 billion in 2024, then fell by 20.0% to -$3.6 billion in 2025, then decreased by 5.21% to -$3.7 billion in 2026.
  • Per Business Quant, the three most recent readings for TEVA's Enterprise Value are -$3.7 billion (Q1 2026), -$3.6 billion (Q4 2025), and -$2.2 billion (Q3 2025).